1-苯基-2-(吡啶-2-基)乙胺
|
|
|
- CAS号:
- 61890-25-3
- 英文名:
- 1-phenyl-2-(pyridin-2-yl)ethanamine
- 英文别名:
- (Rac)-Lanicemine;rac-Lanicemine 2HCl;1-Phenyl-2-(2-pyridinyl)ethanamine;1-phenyl-2-(pyridin-2-yl)ethanamine
- 中文名:
- 1-苯基-2-(吡啶-2-基)乙胺
- 中文别名:
- (RAC)-拉尼西明;1-苯基-2-(吡啶-2-基)乙胺;化合物 (RAC)-LANICEMINE;1-苯基-2-(吡啶-2-基)乙烷-1-胺
- CBNumber:
- CB72617575
- 分子式:
- C13H14N2
- 分子量:
- 198.26
- MOL File:
- 61890-25-3.mol
|
|
|
1-苯基-2-(吡啶-2-基)乙胺化学性质
-
沸点:
-
160 °C(Press: 2 Torr)
-
|
-
密度:
-
1.097±0.06 g/cm3(Predicted)
-
|
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
DMSO: 100 mg/mL (504.39 mM)
-
|
-
酸度系数(pKa):
-
8.29±0.10(Predicted)
-
|
1-苯基-2-(吡啶-2-基)乙胺性质、用途与生产工艺
(Rac)-Lanicemine ((Rac)-AZD6765) 是 Lanicemine 的外消旋体。Lanicemine (AZD6765) 是一种低捕获的 NMDA 受体拮抗剂，Ki 为 0.56-2.1 μM。CHO 和爪蟾卵母细胞中，IC50 分别为 4-7 μM 和 6.4 μM。具有抗抑郁作用。
Lanicemine produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.
Lanicemine (3, 10 or 30 mg/kg; intraperitoneal) not only engages brain circuits involved in the generation of gamma- electroencephalography (EEG), but also influences these networks independent of the broader systems-level disruptions typical of ketamine.
|
Animal Model:
|
Male Sprague-Dawley rats
|
|
Dosage:
|
3, 10 or 30 mg/kg
|
|
Administration:
|
Intraperitoneal
|
|
Result:
|
Produced pronounced dose-dependent elevations in spontaneous gamma-band EEG, but only gamma changes for Ketamine were tightly coupled to increases in locomotor activity.
|
1-苯基-2-(吡啶-2-基)乙胺
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/04/30 | HY-108235B | (Rac)-Lanicemine | | 5 mg | 312元 |
| 2024/04/30 | HY-108235B | 1-苯基-2-(吡啶-2-基)乙胺
(Rac)-Lanicemine | 61890-25-3 | 10mg | 500元 |
61890-25-3, 1-苯基-2-(吡啶-2-基)乙胺 相关搜索:
- 化合物 (RAC)-LANICEMINE
- (RAC)-拉尼西明
- 1-苯基-2-(吡啶-2-基)乙烷-1-胺
- 1-苯基-2-(吡啶-2-基)乙胺
- 61890-25-3
- (Rac)-Lanicemine
- rac-Lanicemine 2HCl
- 1-Phenyl-2-(2-pyridinyl)ethanamine
- 1-phenyl-2-(pyridin-2-yl)ethanamine